ArticleTranslational lung cancer research2025
Prognostic impact of dose to circulating blood cells in non-small cell lung cancer patients after chemoradiotherapy.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe radiation-induced lymphopenia (SRIL) is an adverse effect in which lymphocyte counts drop below a defined threshold after radiotherapy. This study aimed to identify key dosimetric factors associated with SRIL and survival in non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy (CRT). Methods: A total of 241 NSCLC patients treated with definitive CRT were retrospectively analyzed. Baseline blood counts and dosimetric parameters of normal organs, including circulating blood, were assessed to identify predictors of SRIL and evaluate their impact on survival. SRIL was defined as an absolute lymphocyte count (ALC) nadir of <200/µL. Circulating blood dose was estimated using both stochastic and deterministic models: the hematological dose (HEDOS) model and the effective dose to immune cells (EDIC), respectively. Multivariate logistic regression identified predictors of SRIL, while multivariate Cox regression and Kaplan-Meier analyses evaluated prognostic effects on survival. Generalized additive models (GAM) assessed nonlinear associations. Results: SRIL occurred in 68 patients (28.2%) during treatment. The median overall survival (OS) and progression-free survival (PFS) for the entire cohort were 35.0 [95% confidence interval (CI): 29.0-41.0] and 10.0 months (95% CI: 8.0-12.0), respectively. Higher minimum blood dose [HEDOS D100, odds ratio (OR) 1.26, P=0.04], increased lung volume receiving ≥10 Gy (Lung V10, OR 1.03, P=0.02), lower baseline ALC (OR 1.00, P=0.02), and hemoglobin (OR 0.82, P=0.04) were significant predictors of SRIL. GAM identified a critical threshold of 8.29 Gy for HEDOS D100, above which survival outcomes were significantly worse, with shorter median OS (18.0 Conclusions: HEDOS D100 is a strong predictor of SRIL and survival, highlighting the importance of minimizing radiation exposure to circulating blood during CRT to improve clinical outcomes in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.